Study S000609

A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00960661
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 1036
Start: 2009-09
Primary completion: 2012-08
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:exenatide; DRUG:insulin lispro; DRUG:Metformin; DRUG:Insulin/ Glargine
Results posted: TRUE

Registered primary outcomes

Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30 [Baseline, 30 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016788	Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diamant M, Diabetes care	2014	Randomized trial	PMID 25011946 DOI	cites ClinicalTrials.gov:NCT00960661; registry reference RESULT:25011946
R0047508	Improved Treatment of Type 2 Diabetes: Results from the 4B Trial Brian D. Hoyle, MD Conference Express	2013	Randomized trial	DOI	cites ClinicalTrials.gov:NCT00960661